Benefit-risk assessment of the use of toxic botanical drugs in superiority field: a case study on Aconitum carmichaeli Debx
The study, utilizing <i>Fuzi</i> in the treatment of RA as an example, effectively explored the methodology of BRA for toxic botanical drugs. It simulated medication regimens that were more favorable to patients and established a solid foundation for risk management and the rational use of toxic TCM in clinical practice. However, interpretation of the findings should account for limitations in the underlying data.
Authors
- Congcong Qu (ORCID: https://orcid.org/0000-0003-1769-6932)
- Xing Liu (ORCID: https://orcid.org/0000-0002-7480-5085)
- Bing Zhang (ORCID: https://orcid.org/0000-0002-9725-2524)
- Xi Zhang (ORCID: https://orcid.org/0000-0002-4638-3997)
- Zhijian Lin
- Jintao Lyv
Institutions
- Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-03-11
- DOI
- https://doi.org/10.3389/fphar.2025.1505986
- Primary Topic
- Plant-based Medicinal Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- State Administration of Traditional Chinese Medicine of the People's Republic of China